Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

Other illness

• Dementia, mental alteration or psychiatric pathology influencing patient consent procedure and/or protocol observance and study follow-up.

Other

• Patient with progression after the first evaluation of initial treatment.
• Pregnancy and breast-feeding.
• Patient under tutorship or guardianship.
• Patient enable to protocol follow-up for psychological, social, familial or geographical reasons.

• Patient with lung cancer at any diagnostic stage and histology.
• Patient willing to use the follow-up setting with Moovcare® Lung apps.
• Age ≥ 18 years.
• Patient received anti-cancer treatment (surgery, chemotherapy, radiation (stereotaxy or not) or radio-chemotherapy association ended less than 12 weeks (Cohort 1 post-treatment); or during maintenance treatment or consolidation by chemotherapy or targeted therapy, or by immunotherapy initiated less than 12 weeks (Cohort 2 during treatment).
• Imaging tumor evaluation less than 12 weeks showing disease control (response or stability according to RECIST 1.1 criteria).
• Patient with symptomatic score on Moovcare® Lung apps less than 7.
• Patient (or relatives) with internet access, a personnal e-mail box and a smartphone.
• Patient with social security affiliation.
• Signed informed consent form.